Psilocybin for End-of-Life Anxiety: The Research on Death and Dying
About This Video
The earliest rigorous modern psilocybin research focused on end-of-life anxiety in cancer patients — a population facing existential distress that conventional anxiolytics address poorly. This NYU Langone presentation reviews the landmark 2016 trials from NYU and Johns Hopkins, which showed dramatic reductions in anxiety and depression in terminal cancer patients that persisted through 6-month follow-up.
The video captures something the journal articles cannot: the qualitative accounts from participants. Many describe experiences of unity, love, and the dissolution of fear of death that are difficult to categorize clinically but are consistent across participants regardless of prior religious belief. The researchers are careful to distinguish between psilocybin causing a 'religious experience' versus producing a state in which the brain processes existential threat differently — the latter framing has more traction in the literature.
Key Takeaways
- 2016 NYU and Johns Hopkins trials showed significant reductions in anxiety and depression in terminal cancer patients lasting 6+ months after a single session.
- Effect sizes were among the largest ever recorded for any psychiatric intervention in this population.
- Participants consistently reported reduced fear of death, not because they denied death, but because their relationship to it shifted.
- The mystical experience scale — measuring unity, sacredness, and noetic quality — is the strongest predictor of positive outcomes across all psilocybin indications.
- End-of-life psilocybin access is being explored in hospice settings in Oregon and Colorado, where licensed facilitators can legally work with this population.
Dive Deeper
Continue exploring this topic on LearnShrooms: